Search clinical trials for: Eligible for adjuvant or neoadjuvant chemotherapy

Total 409153 results

Jules Bordet Institute

Withdrawn

TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen (TRIUMPH)

Breast Cancer

Belgium
Case Comprehensive Cancer Center

Not yet recruiting

Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

Muscle Invasive Bladder Carcinoma | Malignant Neoplasm of Bladder

United States
Clinica Universidad de Navarra, Universidad de...
Asociación de Amigos de la Universidad de Navarra

Recruiting

SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery (SUROVA)

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Epithelial Ovarian Cancer

Spain
Osaka University

Recruiting

A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer (AMBITION)

Rectal Cancer

Japan
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
Rutgers, The State University of New Jersey

Recruiting

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

Pancreatic Cancer

United States
Shanghai Zhongshan Hospital
Bristol-Myers Squibb

Recruiting

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Esophageal Squamous Cell Carcinoma

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Chemotherapy | Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy

China
M.D. Anderson Cancer Center

Recruiting

Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Erasmus Medical Center
Dutch Cancer Society; Dutch Pancreatic Cancer Group

Recruiting

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer (PREOPANC-3)

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Adenocarcinoma

Netherlands, Sweden, Norway
Kuwait Cancer Control Center

Recruiting

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Kuwait
State Scientific Centre of Coloproctology, Russian...

Recruiting

Total Neoadjuvant Therapy in Rectal Cancer Treatment

Rectal Cancer

Russian Federation
Fundación GECP

Recruiting

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Non Small Cell Lung Cancer | EGFR Gene Mutation

Spain
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Triple Negative Breast Cancer

China
AstraZeneca

Recruiting

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)

Non-Small Cell Lung Cancer

China, United States, Chile, Vietnam, Thailand, Brazil, Bulgaria, Canada, Germany, India, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Turkey, Austria, Israel, Spain, Taiwan, Mexico, France, Italy, Peru, Switzerland, United...
Icahn School of Medicine at Mount Sinai

Recruiting

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Stomach Cancer | Gastric Cancer

United States
Shanghai Henlius Biotech

Not yet recruiting

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
Asan Medical Center

Recruiting

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Shengjing Hospital

Not yet recruiting

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

Breast Cancer

China
Lei Li

Recruiting

NAC Followed by RH for the Treatment of LACC

Laparotomy | Laparoscopy | Locally Advanced Cervical Cancer | Neoadjuvant Chemotherapy | Adjuvant Therapy | Concurrent Chemoradiotherapy | Radical Hysterectomy | Objective Response | Systematic Chemotherapy

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

United States
Institute of Cancer Research, United Kingdom
AstraZeneca

Recruiting

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX)

Breast Neoplasm

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; Verastem, Inc.

Recruiting

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

United States
Krankenhaus Nordwest
German Research Foundation

Recruiting

Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (GAIN)

Biliary Tract Cancer | Incidental Gallbladder Carcinoma

Germany
OBI Pharma, Inc

Recruiting

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Triple Negative Breast Cancer

China, Taiwan, United States, Korea, Republic of, Australia, Brazil, Hong Kong, Mexico, Russian Federation, South Africa, Ukraine, Peru, Poland
LI XIN-XIANG

Recruiting

Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

Rectal Neoplasms

China
Qamar Khan

Recruiting

Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer (HERMET)

HER2-positive Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH)

Muscular Atrophy, Spinal

Belgium, United States, China, Spain, Japan, Canada, France, Poland, Brazil, Croatia, Italy, Russian Federation, Turkey, Germany, Serbia, United Kingdom
Palleos Healthcare GmbH
Roche Pharma AG; Cankado GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP

Completed

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (TP-II)

Breast Neoplasms

Germany
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Switzerland, Australia
Bristol-Myers Squibb

Active, not recruiting

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Russian Federation, Belgium, United States, Australia, Argentina, Brazil, Canada, China, Czechia, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Completed

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)

Breast Cancer

China, Russian Federation, United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, Ireland, Korea, Republic of, Mexico, Netherlands, Poland, Portuga... and more
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

Head and Neck Cancer
Merck Sharp & Dohme LLC
Astellas Pharma Inc; Seagen Inc.

Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

Bladder Cancer

Hungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more
Wuhan Union Hospital, China

Withdrawn

Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation

Colorectal Cancer | Liver Metastases | Radiotherapy

China
University of Arkansas

Completed

Vaccination of Triple Negative Breast Cancer Patients

Breast Neoplasms | Triple Negative Breast Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Breast Cancer

Japan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866)

Bladder Cancer

Canada, United States, Australia, Belgium, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Sweden, Thailand, Turkey, Ukraine, United Kingdom
University of Nebraska
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Institut de Cancérologie de Lorraine

Active, not recruiting

Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

Pancreatic Carcinoma

France
ARCAGY/ GINECO GROUP
AstraZeneca

Active, not recruiting

Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV)

Ovarian Cancer

France
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

Malignant Mesothelioma

United States
Children's Oncology Group
National Cancer Institute (NCI); SWOG Cancer Research Network

Completed

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

Sarcoma

United States, Canada, Australia, Switzerland, Puerto Rico, Netherlands, New Zealand
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Non-small Cell Lung Cancer

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Estonia, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Poland, Romania, Russian Federation, South Africa, Spain, Taiwan, U... and more
Amgen
Austrian Breast and Colorectal Cancer Study Group

Completed

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Breast Cancer

Austria, Sweden
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Triple Negative Breast Neoplasms

Brazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey
Memorial Sloan Kettering Cancer Center

Completed

Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients

Breast Cancer | Peripheral Neuropathy

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Sunnybrook Health Sciences Centre

Active, not recruiting

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Melanoma

Canada
Spanish Lung Cancer Group

Completed

Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer (NATCH)

Non-Small-Cell Lung Cancer

Search clinical trials for: Eligible for adjuvant or neoadjuvant chemotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations